DarioHealth Corp. (NASDAQ: DRIO), an AI-powered healthcare technology company, announced that a review by the Managed Care Services Team of Aon plc supports estimated annual healthcare cost savings of 2.5% to 7.2% for covered populations using its chronic condition management services. For a representative population of 20,000 covered lives, that translates to approximately $3.8 million to $10.8 million in annual savings, according to the review.
The Aon review evaluated 17 studies spanning cardiometabolic, musculoskeletal, and behavioral health conditions, including both independently conducted and company-sponsored research. Aon found consistent reported improvements across clinical, behavioral, healthcare utilization, and cost measures, concluding that the evidence supports an association between DarioHealth services and meaningful clinical and financial outcomes. The review also estimated that management of multiple conditions and access to physicians, which were excluded from the initial calculations, could contribute an additional 1.6 to 2.8 percentage points in savings.
However, Aon did not independently verify the underlying data or audit the studies, and its findings do not guarantee future savings or outcomes for individual customers. The full press release can be viewed at https://ibn.fm/IFvLH.
This news matters because rising healthcare costs continue to pressure employers, health plans, and health systems. If DarioHealth's platform can deliver the savings Aon's review suggests, it could offer a scalable solution for managing chronic conditions, which account for a significant portion of healthcare spending. DarioHealth's integrated platform combines connected devices, personalized member engagement, AI-driven insights, and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal, and behavioral health needs. Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, the AI platform personalizes care at the individual member level by analyzing biometric, clinical, and behavioral data to deliver more timely and effective interventions.
For investors, the Aon review provides third-party validation of DarioHealth's value proposition, potentially strengthening its position with payers and employers. The latest news and updates relating to DRIO are available in the company's newsroom at https://ibn.fm/DRIO. The announcement was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, article and editorial syndication to more than 5,000 outlets, press release enhancement, social media distribution, and corporate communications solutions. For full terms of use and disclaimers, visit https://www.BioMedWire.com/Disclaimer.
